Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraprostatic mepivacaine-adrenaline before ProstaLund Feedback Treatment for symptomatic benign prostatic hyperplasia
2004-000651-42Phase 2Active
- Sponsor
- ProstaLund
- Start
- Jun 2004
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mepivacaine and epinephrine in benign prostatic hyperplasia (BPH), sponsored by ProstaLund. Primary endpoints: Microwave energy required to complete treatment and Patient comfort improvement. Started Jun 2004; status: active.
02
Drugs
mepivacaineepinephrine
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2004-000651-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000651-42.